Myoclonic status epilepticus following repeated oral ingestion of colloidal silver.
about
Central nervous system toxicity of metallic nanoparticlesOn the toxicity of therapeutically used nanoparticles: an overviewSynthesis and Anticancer Properties of Silver(I) Complexes Containing 2,6-Bis(substituted)pyridine DerivativesShort term serum pharmacokinetics of diammine silver fluoride after oral application.Critical observations on the neurotoxicity of silver.Mechanisms of nanosilver-induced toxicological effects: more attention should be paid to its sublethal effects.Effects of particle size and coating on toxicologic parameters, fecal elimination kinetics and tissue distribution of acutely ingested silver nanoparticles in a mouse model.The release of nanosilver from consumer products used in the homeDifferential Effects of Silver Nanoparticles and Silver Ions on Tissue Accumulation, Distribution, and Toxicity in the Sprague Dawley Rat Following Daily Oral Gavage Administration for 13 Weeks4-Alkylated Silver-N-Heterocyclic Carbene (NHC) Complexes with Cytotoxic Effects in Leukemia Cells.Imidazolium and benzimidazolium-containing compounds: from simple toxic salts to highly bioactive drugs.Argyria -- case report.A health surveillance case study on workers who manufacture silver nanomaterials.The inhibitory effects of nano-Ag on voltage-gated potassium currents of hippocampal CA1 neurons.In vivo liberation of silver ions from metallic silver surfaces.Pharmaceutical aspects of silver nanoparticles.Orthopaedic device-related infection: current and future interventions for improved prevention and treatment.
P2860
Q28084729-99B28E1E-CF16-43DC-8799-AE79F315AB23Q28393180-88FCB3E3-F3F0-48D6-83EF-419BFFEDCF4FQ34425825-D13BD18E-57C1-4E0A-BB83-74E048BFD501Q34526443-EEC457EE-5482-43F3-A5F9-57C79C98C0DFQ34622129-E403B7C5-E174-4304-9B13-6D0F1E6DFD7EQ35567368-65DF6BBC-9993-4152-9CE1-513776F8B75AQ36619973-526AFBDE-CE6E-43C2-9E55-882597300F0DQ36638741-8E23422E-C06E-44D1-8FDC-3191A663EB79Q37228586-E4A33DCF-6810-4B79-8803-5C660B4BF2CFQ38845686-A241BC28-CFB3-464B-840D-BFFC7FBB1912Q39065508-E63B6785-1E3D-4D17-9DA4-0D7C8261ADB8Q42015336-CED520C8-4A33-4C9C-9027-2285362A9AD3Q43811032-2CDA0C87-DD63-47D4-B545-F5414E49047FQ48165230-1A4C28DA-853D-45A8-9097-D35A02140355Q48369282-6EB2F0C0-0C75-4C10-B345-F6F1FC5F8455Q49901593-0B011330-CE34-4CAD-BA44-3CFE5D6FB70DQ50893725-6105396A-3BA5-4372-9AF9-E86E7A7A3713
P2860
Myoclonic status epilepticus following repeated oral ingestion of colloidal silver.
description
2004 nî lūn-bûn
@nan
2004 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Myoclonic status epilepticus following repeated oral ingestion of colloidal silver.
@ast
Myoclonic status epilepticus following repeated oral ingestion of colloidal silver.
@en
type
label
Myoclonic status epilepticus following repeated oral ingestion of colloidal silver.
@ast
Myoclonic status epilepticus following repeated oral ingestion of colloidal silver.
@en
prefLabel
Myoclonic status epilepticus following repeated oral ingestion of colloidal silver.
@ast
Myoclonic status epilepticus following repeated oral ingestion of colloidal silver.
@en
P2093
P1433
P1476
Myoclonic status epilepticus following repeated oral ingestion of colloidal silver.
@en
P2093
P304
P356
10.1212/01.WNL.0000120671.73335.EC
P407
P577
2004-04-01T00:00:00Z